Fundraising FoxElektrofi
AcquiredBoston, US · 8 known investors
Find your way into Elektrofi
Sign up to see every warm intro you have to Elektrofi
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Elektrofi team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Acquired by Halozyme Therapeutics October 2025 · $750M ($750M upfront, up to $900M with milestones) · source ↗
Elektrofi is a biotech company developing an ultra-high concentration microparticle formulation platform that enables subcutaneous delivery of biologic medicines such as monoclonal antibodies. It partners with pharmaceutical companies to reformulate therapies for self-administration.
Founders & leadership
Investors · 8
How we know: the company's own site · Not right? Tell us
How we know: the company's own site · Not right? Tell us
How we know: Catalio Capital Management, LP's portfolio page · Not right? Tell us
How we know: Charlotte Angel Fund's portfolio page · Not right? Tell us
.png)
How we know: General Catalyst's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$154.8M disclosed across 2 rounds · 2022–2024
▶$112.3MraisedOct 2024 · 21 investors · BiotechnologyRule 506(b)
- Andrew GoldbergDirector
- Chase CoffmanDirector, Executive Officer
- Constantine ChinoporosDirector
- Charles L. CooneyDirector
- Peter BojoDirector
- Arman GuptaDirector
- Noel JeeDirector
- Jason NorrisDirector, Executive Officer
- Offering amount
- $112.3M
- Amount sold
- $112.3M
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$42.5MraisedJun 2022 · 23 investors · BiotechnologyRule 506(b)
- Sam HuangDirector
- Chase CoffmanExecutive Officer, Director
- Jason NorrisExecutive Officer, Director
- Charles L. CooneyDirector
- Andrew GoldbergDirector
- Constatine ChinoporosDirector
- Offering amount
- $42.5M
- Amount sold
- $42.5M
- First sale
- May 2022
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
2 people who came through Elektrofi went on to found or lead other companies.
Frequently asked questions
- What does Elektrofi do?
- Elektrofi is a biotech company developing an ultra-high concentration microparticle formulation platform that enables subcutaneous delivery of biologic medicines such as monoclonal antibodies. It partners with pharmaceutical companies to reformulate therapies for self-administration.
- Who founded Elektrofi?
- Elektrofi was founded by Chase Coffman.
- Who are Elektrofi's investors?
- Elektrofi's investors include Biotechnology Value Fund, Novo Holdings, Catalio Capital Management, LP, Charlotte Angel Fund, General Catalyst, RA Capital, SR One Capital Management, Sofinnova Ventures.
- How much funding has Elektrofi raised?
- Elektrofi has disclosed $154.8M raised across 2 rounds.
- Where is Elektrofi headquartered?
- Elektrofi is headquartered in Boston, US.